Other Pulmonary fibrosis drug developer Avalyn files IPO PharmaphorumAvalyn Pharma hops on the IPO train, filing to list on the Nasdaq and raise funds for late-stage trials of its inhaled pulmonary fibrosis therapies.OtherRespiratoryRead full story pharminent April 9, 2026 (Last updated: April 9, 2026) Pharmaphorum Avalyn Pharma hops on the IPO train, filing to list on the Nasdaq and raise funds for late-stage trials of its inhaled pulmonary fibrosis therapies. OtherRespiratoryRead full story Post navigation Previous: Avalyn plots IPO to push inhaled pulmonary fibrosis pipeline through clinicNext: Lilly launches GLP-1 pill, kicking off showdown with Novo Nordisk Related Stories Other ‘Seismic shift’ as obesity overtakes cancer for R&D returns pharminent May 5, 2026 Other 223: An Interview With Dr. Antn Blatnik on the Molecular Mechanisms Driving Neuromuscular Disease pharminent May 4, 2026 Other FDA tests out ‘real-time’ clinical trials; AbbVie closes in on a KRAS biotech pharminent April 29, 2026
